Elektrofi
Elektrofi develops hyper concentration microparticle technology for subcutaneous biologic medicine delivery.
About Elektrofi
Elektrofi develops biologic therapies through its hyper concentration microparticle platform technology, Hypercon. The company focuses on reengineering medicine delivery to support partners and patients with smarter administration methods. Elektrofi collaborates with other biopharma companies to develop new generation medicines that can be delivered subcutaneously.
Company Facts
- Headquarters
- Boston
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00051_00100
- Funding Stage
- m_and_a
- Total Funding
- $154,106,920
- Last Funding Type
- series_c
- Last Funding Date
- 2024-08-22
- Website
- elektrofi.com
Industries & Categories
Alternative Medicine, Biotechnology, Therapeutics
Social Links
Canonical: https://fsome.com/organization/elektrofi-89818 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.